Neuroscience
An article in The Times (U.K.):
Blood test could predict severity of multiple sclerosis
Mark Henderson, Science Editor
August 31, 2009
[snip]
Patients whose MS is thought likely to progress quickly could be started swiftly on therapies that can reduce the frequency and severity of attacks, while those at lower risk could be spared medication they do not need immediately. More accurate ways of assessing prognosis could also help to prepare patients for what they should expect in the future, removing the uncertainty that can be a distressing feature of the disease.
[snip]
Read the full article
Dr. Rachel Farrell, of the Institute of Neurology at University College London, is the principal investigator.
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Multiple Sclerosis And Tysabri: Fda
From the FDA: FOR IMMEDIATE RELEASE P04-107 November 23, 2004 Full press release Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA First Monoclonal Antibody Treatment For Multiple Sclerosis Approved FDA today licensed a...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...
Neuroscience
Multiple Sclerosis
An article in The Times (U.K.):
Blood test could predict severity of multiple sclerosis
Mark Henderson, Science Editor
August 31, 2009
[snip]
Patients whose MS is thought likely to progress quickly could be started swiftly on therapies that can reduce the frequency and severity of attacks, while those at lower risk could be spared medication they do not need immediately. More accurate ways of assessing prognosis could also help to prepare patients for what they should expect in the future, removing the uncertainty that can be a distressing feature of the disease.
[snip]
Read the full article
Dr. Rachel Farrell, of the Institute of Neurology at University College London, is the principal investigator.
- Fda: Progressive Multifocal Leukoencephalopathy (pml) And Tysabri (natalizumab)
From the FDA: FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri For Immediate Release: January 20, 2012 [snip]"Today, the U.S. Food and Drug Administration allowed marketing of the first test to...
- Fda Approves Multiple Sclerosis Drug, Ampyra (dalfampridine) Extended-release
From FierceBiotech: FDA approves Acorda's new MS drug January 22, 2010 — 4:49pm ET By John Carroll [snip] The FDA announced Friday afternoon that it has approved Ampyra (dalfampridine) extended-release tablets to improve walking in patients with...
- Business World: Biogen Idec, Elan, Tysabri (natalizumab), And Multiple Sclerosis
From Bloomberg via the New York Times:Move to Reinstate Multiple Sclerosis Drug Published: September 21, 2005 By Bloomberg News Biogen Idec Inc. and the Elan Corporation said yesterday that they would seek federal regulatory approval to resume sales...
- Multiple Sclerosis And Tysabri: Fda
From the FDA: FOR IMMEDIATE RELEASE P04-107 November 23, 2004 Full press release Media Inquiries: 301-827-6242 Consumer Inquiries: 888-INFO-FDA First Monoclonal Antibody Treatment For Multiple Sclerosis Approved FDA today licensed a...
- Multiple Sclerosis And Antegren/tysabri
From the CBC:Health Canada fast tracks review of multiple sclerosis drug Last Updated Mon, 22 Nov 2004 21:28:46 EST TORONTO - Some Canadians with multiple sclerosis are encouraged by the early results of a study on a new kind of treatment for the...